• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

房颤消融术后生活质量和医疗保健利用率的改善。

Quality of life and healthcare utilisation improvements after atrial fibrillation ablation.

机构信息

Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, UK

Heart Center, Jessa Hospital, Hasselt, Belgium.

出版信息

Heart. 2021 Aug;107(16):1296-1302. doi: 10.1136/heartjnl-2020-318676. Epub 2021 May 5.

DOI:10.1136/heartjnl-2020-318676
PMID:33952593
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8327410/
Abstract

OBJECTIVE

Pulmonary vein isolation (PVI) guided by a standardised CLOSE (contiguous optimised lesions) protocol has been shown to increase clinical success after catheter ablation for paroxysmal atrial fibrillation (PAF). This study analysed healthcare utilisation and quality of life (QOL) outcomes from a large multicentre prospective study, measured association between QOL and atrial fibrillation (AF) burden and identified factors associated with lack of QOL improvement.

METHODS

CLOSE-guided ablation was performed in 329 consecutive patients (age 61.4 years, 60.8% male) with drug-refractory PAF in 17 European centres. QOL was measured at baseline and 12 months post-ablation via Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) and EuroQoL EQ-5D-5L questionnaires. All-cause and cardiovascular hospitalisations and cardioversions over 12 months pre-ablation and post-ablation were recorded. Rhythm monitoring included weekly and symptom-driven trans-telephonic monitoring, plus ECG and Holter monitoring at 3, 6 and 12 months. AF burden was defined as the percentage of postblanking tracings with an atrial tachyarrhythmia ≥30 s. Continuous measures across multiple time points were analysed using paired t-tests, and associations between various continuous measures were analysed using independent sample t-tests. Each statistical test used two-sided p values with a significance level of 0.05.

RESULTS

Both QOL instruments showed significant 12-month improvements across all domains: AFEQT score increased 25.1-37.5 points and 33.3%-50.8% fewer patients reporting any problem across EuroQoL EQ-5D-5L domains. Overall, AFEQT improvement was highly associated with AF burden (p=0.009 for <10% vs ≥10% burden, p<0.001 for <20% vs ≥20% burden). Cardiovascular hospitalisations were significantly decreased after ablation (42%, p=0.001). Patients without substantial improvement in AFEQT (55/301, 18.2%) had higher AFEQT and CHADS-VASc scores at baseline, and higher AF burden following PVI.

CONCLUSIONS

QOL improved and healthcare utilisation decreased significantly after ablation with a standardised CLOSE protocol. QOL improvement was significantly associated with impairment at baseline and AF burden after ablation.

TRIAL REGISTRATION NUMBER

NCT03062046.

摘要

目的

在标准的 CLOSE(连续优化病变)方案指导下进行肺静脉隔离(PVI)已被证明可增加导管消融阵发性心房颤动(PAF)后的临床成功率。本研究通过一项大型多中心前瞻性研究分析了医疗保健的利用情况和生活质量(QOL)结果,测量了 QOL 与心房颤动(AF)负担之间的关联,并确定了与 QOL 改善不足相关的因素。

方法

在 17 个欧洲中心对 329 例药物难治性 PAF 的连续患者(年龄 61.4 岁,60.8%为男性)进行了 CLOSE 引导消融。通过心房颤动对生活质量影响调查(AFEQT)和欧洲五维健康量表(EQ-5D-5L)问卷在基线和消融后 12 个月测量 QOL。记录消融前 12 个月和消融后所有原因和心血管住院和电复律。节律监测包括每周和症状驱动的远程电话监测,以及消融后 3、6 和 12 个月的心电图和动态心电图监测。AF 负担定义为空白后描记中≥30 秒的房性心动过速/心房颤动的百分比。使用配对 t 检验分析多个时间点的连续测量值,使用独立样本 t 检验分析各种连续测量值之间的关联。每个统计检验均使用双侧 p 值,显著性水平为 0.05。

结果

两种 QOL 工具在所有领域均显示出 12 个月的显著改善:AFEQT 评分增加了 25.1-37.5 分,在欧洲五维健康量表(EQ-5D-5L)领域报告任何问题的患者比例减少了 33.3%-50.8%。总体而言,AFEQT 的改善与 AF 负担高度相关(p=0.009,<10%与≥10%的负担,p<0.001,<20%与≥20%的负担)。消融后心血管住院率显著下降(42%,p=0.001)。在 AFEQT 中没有显著改善的患者(55/301,18.2%)在基线时的 AFEQT 和 CHADS-VASc 评分较高,并且在 PVI 后 AF 负担较高。

结论

使用标准的 CLOSE 方案进行消融后,QOL 显著改善,医疗保健利用率降低。QOL 的改善与基线时的损伤和消融后的 AF 负担显著相关。

试验注册编号

NCT03062046。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/3b933d9dde17/heartjnl-2020-318676f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/adbf6cf440bb/heartjnl-2020-318676f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/a92c9e46c6e6/heartjnl-2020-318676f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/16e5a5d970ba/heartjnl-2020-318676f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/00df393f2c20/heartjnl-2020-318676f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/268a8f7d4ea2/heartjnl-2020-318676f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/3b933d9dde17/heartjnl-2020-318676f06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/adbf6cf440bb/heartjnl-2020-318676f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/a92c9e46c6e6/heartjnl-2020-318676f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/16e5a5d970ba/heartjnl-2020-318676f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/00df393f2c20/heartjnl-2020-318676f04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/268a8f7d4ea2/heartjnl-2020-318676f05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d6/8327410/3b933d9dde17/heartjnl-2020-318676f06.jpg

相似文献

1
Quality of life and healthcare utilisation improvements after atrial fibrillation ablation.房颤消融术后生活质量和医疗保健利用率的改善。
Heart. 2021 Aug;107(16):1296-1302. doi: 10.1136/heartjnl-2020-318676. Epub 2021 May 5.
2
Catheter ablation for persistent atrial fibrillation: patterns of recurrence and impact on quality of life and health care utilization.导管消融治疗持续性心房颤动:复发模式及其对生活质量和医疗保健利用的影响。
Eur Heart J. 2024 Aug 3;45(29):2604-2616. doi: 10.1093/eurheartj/ehae291.
3
Association Between Quality of Life and Procedural Outcome After Catheter Ablation for Atrial Fibrillation: A Secondary Analysis of a Randomized Clinical Trial.房颤导管消融术后生活质量与手术结局的相关性:一项随机临床试验的二次分析。
JAMA Netw Open. 2020 Dec 1;3(12):e2025473. doi: 10.1001/jamanetworkopen.2020.25473.
4
Biatrial linear ablation in sustained nonpermanent AF: Results of the substrate modification with ablation and antiarrhythmic drugs in nonpermanent atrial fibrillation (SMAN-PAF) trial.持续性非永久性房颤的双房线性消融:消融和抗心律失常药物治疗非永久性房颤(SMAN-PAF)试验中的基质改良结果。
Heart Rhythm. 2016 Feb;13(2):399-406. doi: 10.1016/j.hrthm.2015.10.006. Epub 2015 Oct 9.
5
Relationship between quality of life and burden of recurrent atrial fibrillation following ablation: CAPCOST multicentre cohort study.生活质量与消融后复发性心房颤动负担的关系:CAPCOST 多中心队列研究。
Europace. 2020 Jul 1;22(7):1017-1025. doi: 10.1093/europace/euaa066.
6
Health-related quality of life changes in patients undergoing repeated catheter ablation for atrial fibrillation.接受反复导管消融治疗心房颤动患者的健康相关生活质量变化
Clin Res Cardiol. 2016 Jan;105(1):1-9. doi: 10.1007/s00392-015-0879-3. Epub 2015 Jun 24.
7
Relationship of quality of life with procedural success of atrial fibrillation (AF) ablation and postablation AF burden: substudy of the STAR AF randomized trial.生活质量与心房颤动(AF)消融程序成功和消融后 AF 负荷的关系:STAR AF 随机试验的亚研究。
Can J Cardiol. 2013 Oct;29(10):1211-7. doi: 10.1016/j.cjca.2013.06.006. Epub 2013 Aug 26.
8
Paroxysmal and persistent atrial fibrillation ablation outcomes with the pulmonary vein ablation catheter GOLD duty-cycled phased radiofrequency ablation catheter: quality of life and 12-month efficacy results from the GOLD Atrial Fibrillation Registry.阵发性和持续性心房颤动消融的结果与肺静脉消融导管 GOLD 定频相控射频消融导管:来自 GOLD 心房颤动登记研究的生活质量和 12 个月疗效结果。
Europace. 2020 Jun 1;22(6):888-896. doi: 10.1093/europace/euaa042.
9
Freedom from paroxysmal atrial fibrillation after successful pulmonary vein isolation with pulmonary vein ablation catheter-phased radiofrequency energy: 2-year follow-up and predictors of failure.肺静脉消融导管-相位射频能量成功隔离肺静脉后阵发性心房颤动的消除:2 年随访及失败预测因素。
Europace. 2012 Jun;14(6):818-25. doi: 10.1093/europace/eus010. Epub 2012 Feb 15.
10
Use of Ablation Index-Guided Ablation Results in High Rates of Durable Pulmonary Vein Isolation and Freedom From Arrhythmia in Persistent Atrial Fibrillation Patients: The PRAISE Study Results.消融指数指导下的消融在持续性心房颤动患者中实现了高比例的持久肺静脉隔离和无心律失常:PRAISE 研究结果。
Circ Arrhythm Electrophysiol. 2018 Sep;11(9):e006576. doi: 10.1161/CIRCEP.118.006576.

引用本文的文献

1
Association between quality of life and redo procedures after pulmonary vein isolation in atrial fibrillation patients: Data from the Netherlands Heart Registration.心房颤动患者肺静脉隔离术后生活质量与再次手术之间的关联:来自荷兰心脏注册研究的数据。
Heart Rhythm O2. 2025 Mar 22;6(6):745-752. doi: 10.1016/j.hroo.2025.03.017. eCollection 2025 Jun.
2
Long-Term Patient-Reported Outcomes After Radiofrequency Ablation and Cryoballoon Ablation for Paroxysmal Atrial Fibrillation: The Effect of Additional Ablations.阵发性心房颤动患者接受射频消融和冷冻球囊消融后的长期患者报告结局:额外消融的影响
J Cardiovasc Dev Dis. 2024 Nov 30;11(12):385. doi: 10.3390/jcdd11120385.
3

本文引用的文献

1
Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation.冷冻消融或药物治疗用于初始治疗心房颤动。
N Engl J Med. 2021 Jan 28;384(4):305-315. doi: 10.1056/NEJMoa2029980. Epub 2020 Nov 16.
2
Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trial.标准化肺静脉隔离工作流程以连续病灶包绕静脉:多中心 VISTAX 试验。
Europace. 2020 Nov 1;22(11):1645-1652. doi: 10.1093/europace/euaa157.
3
Early Rhythm-Control Therapy in Patients with Atrial Fibrillation.心房颤动患者的早期节律控制治疗。
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.
2024年欧洲心律协会/心律协会/亚太心律协会/拉丁美洲心律协会关于心房颤动导管消融和外科消融的专家共识声明
J Arrhythm. 2024 Oct 6;40(6):1217-1354. doi: 10.1002/joa3.13082. eCollection 2024 Dec.
4
Hospital readmissions following catheter ablation for atrial fibrillation with THERMOCOOL™ STSF/ THERMOCOOL™ ST catheter with CARTO™ 3 system versus TactiCath™ catheter with EnSite™ system.使用带有CARTO™ 3系统的THERMOCOOL™ STSF/THERMOCOOL™ ST导管与使用带有EnSite™系统的TactiCath™导管进行房颤导管消融术后的医院再入院情况。
J Comp Eff Res. 2025 Jan;14(1):e240075. doi: 10.57264/cer-2024-0075. Epub 2024 Dec 4.
5
Quality of life improvement from thoracoscopic atrial fibrillation ablation in women versus men: a prospective cohort study.女性与男性经胸腔镜房颤消融术改善生活质量的比较:一项前瞻性队列研究
Interdiscip Cardiovasc Thorac Surg. 2024 Jul 3;39(1). doi: 10.1093/icvts/ivae132.
6
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.2024 年欧洲心律协会/心律学会/亚太心律学会/拉丁美洲心律学会专家共识声明:关于心房颤动的导管和手术消融。
J Interv Card Electrophysiol. 2024 Aug;67(5):921-1072. doi: 10.1007/s10840-024-01771-5.
7
2024 European Heart Rhythm Association/Heart Rhythm Society/Asia Pacific Heart Rhythm Society/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation.2024 年欧洲心脏节律协会/心律学会/亚太心脏节律学会/拉丁美洲心脏节律学会专家共识声明:导管和手术消融治疗心房颤动。
Europace. 2024 Mar 30;26(4). doi: 10.1093/europace/euae043.
8
Atrial fibrillation: better symptom control with rate and rhythm management.心房颤动:通过心率和节律管理实现更好的症状控制。
Lancet Reg Health Eur. 2024 Feb 1;37:100801. doi: 10.1016/j.lanepe.2023.100801. eCollection 2024 Feb.
9
Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study.广泛性焦虑症是心房颤动患者生活质量受损的预测因素:前瞻性观察性 ARENA 研究的结果。
J Psychosom Res. 2024 Jan;176:111542. doi: 10.1016/j.jpsychores.2023.111542. Epub 2023 Nov 8.
10
A Digital Infrastructure for Cardiovascular Patient Care Based on Mobile Health Data and Patient-Reported Outcomes: Concept Details of the Helios TeleWear Project Including Preliminary Experiences.基于移动健康数据和患者报告结局的心血管患者护理数字基础设施:赫利俄斯远程穿戴项目的概念细节及初步经验
JMIR Form Res. 2023 Mar 3;7:e41115. doi: 10.2196/41115.
N Engl J Med. 2020 Oct 1;383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29.
4
Quality of Life and Health Care Utilization in the CIRCA-DOSE Study.CIRCA-DOSE 研究中的生活质量和医疗保健利用情况。
JACC Clin Electrophysiol. 2020 Aug;6(8):935-944. doi: 10.1016/j.jacep.2020.04.017.
5
Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: The CLOSE to CURE study.导管消融对低危阵发性心房颤动患者心律失常负担的长期影响:CLOSE 至 CURE 研究。
Heart Rhythm. 2020 Apr;17(4):535-543. doi: 10.1016/j.hrthm.2019.11.004. Epub 2019 Nov 9.
6
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary.2017年心房颤动导管消融与外科消融专家共识声明:执行摘要(由心律学会/欧洲心律协会/欧洲心血管病预防与康复协会/亚太心律学会/拉丁美洲心脏电生理与心脏起搏学会发布)
Heart Rhythm. 2017 Oct;14(10):e445-e494. doi: 10.1016/j.hrthm.2017.07.009. Epub 2017 Sep 15.
7
Incidence of false-positive transmissions during remote rhythm monitoring with implantable loop recorders.植入式循环记录器远程节律监测中假阳性传输的发生率。
Heart Rhythm. 2020 Jan;17(1):75-80. doi: 10.1016/j.hrthm.2019.07.015. Epub 2019 Jul 16.
8
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score.定义心房颤动对生活质量评分影响的临床重要差异。
Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358. doi: 10.1161/CIRCOUTCOMES.118.005358.
9
Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial.导管消融与药物治疗对心房颤动患者生活质量的影响:CABANA 随机临床试验。
JAMA. 2019 Apr 2;321(13):1275-1285. doi: 10.1001/jama.2019.0692.
10
Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias: Evolution or History Repeating Itself?接触力感应在心律失常导管消融中的作用:是进化还是历史重演?
JACC Clin Electrophysiol. 2018 Jun;4(6):707-723. doi: 10.1016/j.jacep.2018.03.014.